A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors

Trial Profile

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Everolimus (Primary) ; Lapatinib (Primary) ; Nilotinib (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms MOST
  • Most Recent Events

    • 02 Nov 2016 Planned End Date changed from 1 Feb 2020 to 1 Nov 2019.
    • 02 Nov 2016 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2017.
    • 29 Sep 2015 Interim results (n=78) presented at the European Cancer Congress 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top